Navigation Links
The use of placebo in rheumatoid arthritis clinical trials may negatively impact patients
Date:5/27/2011

The results of this study, conducted in Germany, re-open the debate on whether it is ethical to conduct placebo-controlled studies where patients in the placebo-group are at a serious disadvantage compared to patients taking the new treatments. The study analysed current study designs, for new therapies such as abatacept (Orencia), golimumab (Simponi) or tocilizumab (Actemra), and showed that patients in the placebo group experienced no change in medication, having to continue with their former, ineffective treatment plus placebo.

"According to the Helsinki-Declaration of the World Medical Association*, a placebo-controlled study design is deemed to be ethically acceptable when there is no other effective treatment," said Dr. Juche, Johanniter-Hospital, Treuenbrietzen, Germany. "However, this analysis confirms that patients in the placebo-group are at a disadvantage as they are given no change in medication to reduce their active inflammatory condition or halt disease progression. Our recommendation is that future clinical trials should include an active comparator group to ensure that all patients receive effective treatments to improve their quality of life."

In the analysis, researchers used studies from the European Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for abatacept, golimumab and tocilizumab as samples. The studies chosen had to be placebo controlled at the beginning and state clinical relevant outcome criteria (e.g. DAS28**, ACR20***, Health Assessment Questionnaire and joint erosion scores).


'/>"/>

Contact: Rory Berrie
rory.berrie@cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Page: 1

Related biology news :

1. Goji berries have the same nutrients as fruits and vegetables and a placebo effect
2. New therapeutic target identified for rheumatoid arthritis
3. Anakinra for rheumatoid arthritis: A modest benefit with some risk
4. Gene therapy demonstrates benefit in patients with rheumatoid arthritis
5. Researchers identify new risk factor gene for rheumatoid arthritis
6. New trigger for chronic inflammation in rheumatoid arthritis discovered
7. BUSPH study links rheumatoid arthritis to vitamin D deficiency
8. Study confirms link between rheumatoid arthritis and COPD
9. Undertreatment of cardiovascular disease in rheumatoid arthritis patients following a heart attack
10. Geisinger research: Antimalarial drug prevents diabetes in arthritis patients
11. Inhibiting proteins may prevent cartilage breakdown in arthritis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):
(Date:6/28/2017)... ... ... Supplies of the critical medical isotope molybdenum-99 (Mo-99) are secure and reliable ... and Molecular Imaging (SNMMI) 2017 annual meeting in Denver, Colorado in June. Mo-99 ... million nuclear medicine procedures worldwide every year. (1) , Sally Schwarz, President of ...
(Date:6/27/2017)... ... June 27, 2017 , ... Brain State Technologies, a ... campaign on June 15th to fund production of the new B2v2 wearable brainwave ... Kickstarter goal by more than 150% in a little over a week. , ...
(Date:6/27/2017)... ... June 27, 2017 , ... Indiana-based Xylogenics ... yeast production and fermentation process. The efficiencies created by the newest strain ... most notably the ethanol industry wherein individual production plants are planning to invest ...
(Date:6/26/2017)... ... 2017 , ... Third Wave Bioactives, LLC announces the addition of Brett Thompson. ... business development and ensuring quality customer experience. , Brett brings to Third ... technical, marketing and sales roles. “Brett’s background working with customers and eye for market ...
Breaking Biology Technology: